Profile
Sector:
HealthcareCountry:
United StatesIPO:
28 September 2017Website:
http://www.deciphera.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Tue, 11 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
DCPH Latest News
Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.
Japan's Ono Pharmaceutical Co announced on Tuesday that its acquisition of Deciphera Pharmaceuticals for $2.4 billion is the initial move in its expansion into the U.S. and European markets.
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) surged 75% today following ONO Pharmaceutical's (TYO: 4528) announcement of a $2.4 billion acquisition. Deciphera Pharmaceuticals stock is now worth $25.60 per share.
Deciphera Pharmaceuticals (NASDAQ: DCPH) shares are increasing today following the announcement of a $2.4 billion acquisition by ONO Pharmaceutical. Under the agreement, ONO Pharmaceutical will purchase Deciphera Pharmaceuticals for $25.60 per share in cash.
Deciphera Pharmaceuticals is being acquired by ONO Pharmaceutical of Japan in a $2.4 billion deal.
Deciphera Pharmaceuticals announced on Monday that ONO Pharmaceutical Co will purchase the company for $2.4 billion in cash.
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?
The consensus price target hints at a 48.5% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 59.6% in Deciphera Pharmaceuticals, Inc. (DCPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.
- 1(current)
What type of business is Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company that develops drugs for cancer patients by targeting key mechanisms of drug resistance that limit the speed and duration of response to various cancer treatments. The company was founded in 2003 and is based in Waltham, Massachusetts. The company's small molecule drug candidates target an important family of enzymes called kinases, which are known to play a direct role in the growth and spread of many types of cancer. The company is advancing the development of Ripretinib for the treatment of patients with advanced gastrointestinal stromal tumors, which is currently in clinical trials for the treatment of gliomas, melanoma, NSCLC, embryonal carcinoma, penile cancer, and soft tissue sarcomas.
What sector is Deciphera Pharmaceuticals in?
Deciphera Pharmaceuticals is in the Healthcare sector
What industry is Deciphera Pharmaceuticals in?
Deciphera Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry
What country is Deciphera Pharmaceuticals from?
Deciphera Pharmaceuticals is headquartered in United States
When did Deciphera Pharmaceuticals go public?
Deciphera Pharmaceuticals initial public offering (IPO) was on 28 September 2017
What is Deciphera Pharmaceuticals website?
https://www.deciphera.com
Is Deciphera Pharmaceuticals in the S&P 500?
No, Deciphera Pharmaceuticals is not included in the S&P 500 index
Is Deciphera Pharmaceuticals in the NASDAQ 100?
No, Deciphera Pharmaceuticals is not included in the NASDAQ 100 index
Is Deciphera Pharmaceuticals in the Dow Jones?
No, Deciphera Pharmaceuticals is not included in the Dow Jones index
When does Deciphera Pharmaceuticals report earnings?
The next expected earnings date for Deciphera Pharmaceuticals is 09 August 2024